Byonyks initiates U.S. commercial rollout of FDA-cleared X1 automated peritoneal dialysis cycler

In Mid 2025, Chicago-based Byonyks announced it had received U.S. FDA 510(k) clearance for its X1 Automated Peritoneal Dialysis (APD) Cycler, enabling it to commercially introduce its home-based dialysis system to the American market. Having already delivered more than 10,000 therapies internationally through overseas licenses, the company is now building out its U.S. operational infrastructure and planning to begin treating patients stateside.

Byonyks is a MedTech company focused on developing state-of-the-art, home-based dialysis technologies within the global renal care market, with a mission to expand access to life-sustaining therapy worldwide.

For Byonyks Founder and CEO Farrukh Usman, the clearance represents a deeply personal milestone. Usman lost loved ones on dialysis and left a lucrative career in Boston to launch Byonyks with one goal: changing how dialysis is delivered. “Why do we drag our parents to a dialysis center three times a week? Why do they have to feel exhausted at the end of hemodialysis? These people can be treated at home, feel high energy when they get off the machine, and some can return to work and earn income for their families,” he said. “We have proved that with our patient population.”

An underused, clinically superior option

Peritoneal dialysis is a bloodless, home-based therapy that offers patients greater flexibility, a better quality of life, and longer preservation of residual kidney function than in-center hemodialysis. Data from the U.S. Renal Data System show it carries a 10% higher survival rate — yet roughly 85% of Americans on dialysis still receive in-center hemodialysis. Byonyks believes that gap is driven in part by the age of available technology: every peritoneal dialysis device on the market today is between 10 and 30 years old.

“Can you imagine using a 20-year-old phone or car?” Usman said. “The FDA’s clearance of X1 heralds a new era.”

A platform for broader innovation

Chief Innovation Officer Rod Kenley, who holds more than 100 patents, helped establish AAMI dialysis standards and contributed to several earlier breakthrough dialysis products, framed the X1 as a foundation rather than a finish line. “Our advanced development programs are focused on significantly improving clinical outcomes for peritoneal dialysis patients and addressing many of the factors that limit long-term therapy success,” he said.

Chief Medical Officer Andrew King, MD, pointed to the global dimension of the problem: approximately 86% of people worldwide who need dialysis have no access to it. “Byonyks is driven to improve patient lives through transformative innovation that expands global access to dialysis, improves biocompatibility, minimizes metabolic impact, reduces infection risk, and lowers the carbon footprint,” King said.

Up next: MedTech World Asia 2026

As investors, founders, healthcare leaders, and innovators continue exploring new opportunities across global markets, these conversations will take centre stage at the upcoming MedTech World Asia 2026. Taking place in Hong Kong, the event will bring together stakeholders from across the world to discuss investment, commercialisation, regulatory pathways, and the technologies advancing healthcare. Learn more and secure your place at MedTech World Asia 2026.

Ways to participate in MedTech World Asia

• Speak
• Present
• Partner
• Active Investor? Apply for your investor pass